NASDAQ: VCYT · Industrial Applications and Services · 7 alerts · CIK 1384101
Share price
$24.01Close, Nov 16
Market cap
$1.94B
Shares outstanding
80.7MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Veracyte, Inc. filings on SEC EDGAR ↗
Veracyte delivered a Q3 revenue beat but significantly lowered Decipher prostate volume expectations, signaling a transition from outsized guideline-driven growth to a normalized, more competitive market environment.
Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.
“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
Veracyte Insider Jens Holstein Sells $728K of Stock
Jens Holstein sold 15,000 shares of Veracyte, Inc. at $47.00 to $50.00 a share (average $48.50) in 2 transactions, worth $728K in total between Sep 24, 2026 and Oct 27, 2026. Shares held after the trade: 27,471 (-21.4%).
Veracyte Insider Karin Eastham Sells $743K of Stock
Karin Eastham sold 14,850 shares of Veracyte, Inc. at $50.00 a share, worth $743K in total on Oct 27, 2026. Shares held after the trade: 10,247 (-59.2%).
Veracyte Insider Jens Holstein Sells $205K of Stock
Jens Holstein sold 5,000 shares of Veracyte, Inc. at $40.95 a share, worth $205K in total on Sep 14, 2026. Shares held after the trade: 27,471 (-15.4%).
Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.
Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.
Value
$150M
Counterparty
Convergent Genomics Inc.
“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”
Marc Stapley, Veracyte’s chief executive officer
“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”
Brian Slingerland, chief executive officer, Convergent Genomics